Vermeulen V, Coppens K, Kesteloot K
Centre for Health Services and Nursing Research, University of Leuven.
Int J Technol Assess Health Care. 2001 Summer;17(3):316-28. doi: 10.1017/s0266462301106045.
To describe how scientific evidence has influenced healthcare policy making in Belgium in the field of sickness prevention for mammography, PSA testing in prostate cancer screening, and use of ultrasound in pregnancy.
Review of published and gray literature and interviews with stakeholders and experts.
At the end of 1999, a systematic national/regional screening program had not yet been implemented for any of the three screening strategies. A systematic breast cancer screening program is being prepared for implementation only in Flanders. This limited impact can be attributed to the fragmentation in healthcare policy, the different options among the different regions, fragmentation in healthcare practice, the strong impact of healthcare stakeholders (provider groups and sickness funds) on decision making, and limited attention to scientific evidence in health policy and technology assessment.
Health technology assessment has had very little impact on policy and practice in use of mammography, PSA testing, and ultrasound in pregnancy in Belgium.
描述科学证据如何影响比利时在疾病预防领域的医疗政策制定,这些领域包括乳腺钼靶筛查、前列腺癌筛查中的前列腺特异性抗原(PSA)检测以及孕期超声检查。
回顾已发表文献和灰色文献,并采访利益相关者和专家。
1999年底,这三种筛查策略中的任何一种都尚未在全国/地区实施系统的筛查项目。仅在弗拉芒大区正在准备实施一项系统性乳腺癌筛查项目。这种有限的影响可归因于医疗政策的碎片化、不同地区之间的不同选择、医疗实践的碎片化、医疗利益相关者(医疗服务提供方团体和疾病基金)对决策的强烈影响,以及卫生政策和技术评估中对科学证据的关注有限。
在比利时,卫生技术评估对乳腺钼靶检查、PSA检测和孕期超声检查的政策及实践影响甚微。